Evofem Biosciences
12400 High Bluff Drive
Suite 600
San Diego
California
92130
Tel: 858-550-1900
Fax: 844-828-2010
Website: http://www.evofem.com/
Email: info@evofem.com
196 articles about Evofem Biosciences
-
Evofem Presents Data Detailing Fewer Urinary Tract Infections in Women Using Phexxi in the Phase 3 AMPOWER Clinical Trial
5/6/2022
Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced that new data from the Phase 3 AMPOWER clinical trial of Phexxi® (lactic acid, citric acid, and potassium bitartrate) showed that women enrolled in the AMPOWER trial had fewer urinary tract infections (UTIs) compared to the general population.
-
Evofem Biosciences Announces 1-for-15 Reverse Stock Split
5/5/2022
Evofem Biosciences, Inc., announced that the Board and stockholders of the Company approved a 1-for-15 reverse stock split of the Company's common stock at the annual meeting of the Company held on May 4, 2022.
-
Evofem Biosciences Reports First Quarter 2022 Financial Results and Provides Corporate Update
5/4/2022
Evofem Biosciences, Inc., reported financial results for the three-month period ended March 31, 2022.
-
Evofem Improves Phexxi® Patient Experiences Through New Agreement with VitaCare Prescription Services
4/27/2022
Evofem Biosciences, Inc., announced that it has entered into a new agreement with VitaCare Prescription Services, a wholly-owned subsidiary of GoodRx, to provide enhanced "white glove" support services to women prescribed Phexxi® who choose to use VitaCare.
-
Evofem to Present New Research in Gynecological Health at the 2022 American College of Obstetricians and Gynecologists Annual Meeting
4/26/2022
Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced it will present new data from the Phase 3 AMPOWER Clinical Trial at the 2022 American College of Obstetricians and Gynecologists (ACOG) annual meeting.
-
Evofem Biosciences to Report First Quarter 2022 Results and Provide Corporate Update on Wednesday, May 4, 2022
4/25/2022
Evofem Biosciences, Inc., (Nasdaq: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the first quarter ended March 31, 2022.
-
It was yet another busy week for clinical trial news, with a range of studies for COVID-19, various cancers, fungal infections and other indications.
-
Evofem Announces Karina Fedasz as Company's New Head of Business Development
4/11/2022
Evofem Biosciences, Inc., announced the appointment of Karina Fedasz as its Head of Business Development.
-
Evofem Presents Positive Encore Data in Sexually Transmitted Infections Impacting Women at the 2022 Academy of Managed Care Pharmacy Annual Meeting
3/31/2022
Evofem Biosciences, Inc., (Nasdaq: EVFM) today presented data at the Academy of Managed Care Pharmacy (AMCP) annual meeting showing EVO100 (the investigational name for Phexxi®) provided a significant decrease in gonorrhea and chlamydia infections in women as well as additional patient health outcomes related to satisfaction with use of the investigational product.
-
Saundra Pelletier, CEO of Evofem Biosciences, to Receive Honorary Degree from Husson University
3/28/2022
Husson University will hold its 2022 Commencement Ceremony on Saturday, May 7, 2022 at the Cross Insurance Center in Bangor, starting at 10:30 a.m. During the ceremony, Husson University will pay special tribute to Saundra Pelletier, the chief executive officer (CEO), president, and executive director of Evofem Biosciences (Nasdaq: EVFM ) of San Diego, California.
-
The biopharma industry ended February and began March with plenty of clinical trial news. BioSpace shares the highlights.
-
Evofem Completes Enrollment in EVOGUARD Phase 3 Clinical Trial of EVO100 for Prevention of Chlamydia and Gonorrhea in Women
3/4/2022
Evofem Biosciences, Inc., (Nasdaq: EVFM) announced today that it has completed enrollment in EVOGUARD , the registrational Phase 3 clinical trial evaluating EVO100.
-
Evofem Biosciences Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update
3/3/2022
Evofem Biosciences, Inc. (Nasdaq: EVFM), a commercial stage biopharmaceutical company, today reported financial results for the three- and twelve-month periods ended December 31, 2021.
-
Evofem Biosciences to Report Fourth Quarter and Year-End 2021 Results and Provide Corporate Update on Thursday, March 3, 2022
2/17/2022
Evofem Biosciences, Inc., (NASDAQ: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the fourth quarter and year ended December 31, 2021 on Thursday, March 3, 2022 at 4:30 p.m. ET (1:30 p.m. PT).
-
FDA Awards QIDP Designation for Prevention of Chlamydia to Evofem Biosciences
2/9/2022
Evofem Biosciences, Inc., announced today that the U.S. Food and Drug Administration (FDA) has awarded "Qualified Infectious Disease Product" (QIDP) Designation to EVO100 (the investigational name for Phexxi®.
-
Evofem Biosciences to Present at Aegis Virtual Conference on Wednesday, February 23, 2022
2/8/2022
Evofem Biosciences, Inc., (NASDAQ: EVFM) will present at the Aegis Virtual Conference.
-
Evofem Biosciences Announces Record Net Sales and Phexxi Prescriptions in Q4 2021
1/19/2022
Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced strong preliminary results for the fourth quarter of 2021, including record growth in net product sales of its hormone-free prescription contraceptive gel, Phexxi® (lactic acid, citric acid and potassium bitartrate).
-
Phexxi Access to Expand under New Government Guidance Stating Insurers Must Cover FDA-approved Contraceptives with No Out-of-Pocket Costs to Women
1/12/2022
Evofem Biosciences, Inc. (NASDAQ: EVFM) today commended the Health Resources and Services Administration (HRSA) and the U.S. Department of Labor on their separately-issued updated guidance related to contraceptive access.
-
Evofem Biosciences to Present at H.C. Wainwright BioConnect Conference
1/4/2022
Evofem Biosciences, Inc., announced that the Company will present and host one-on-one meetings at the H.C. Wainwright BioConnect Virtual Conference being held from January 10 – 13, 2022.
-
Evofem Biosciences and Orion Biotechnology Launch Collaboration to Develop MPT Product Candidate to Include HIV Prevention
12/16/2021
Evofem Biosciences, Inc. (NASDAQ: EVFM) and Orion Biotechnology Canada Ltd. today announced that they have entered into a collaboration agreement to evaluate the compatibility and stability of Orion's novel CCR5 antagonist, OB-002.